Brancaccio Giuseppina, Gaeta Laura, Vitale Alessandro, Gaeta Giovanni B
Infectious Diseases, University Hospital, Padua, Italy.
Gastroenterology and Endoscopy Unit, Hospital San Paolo, Naples, Italy.
Infez Med. 2022 Jun 1;30(2):204-210. doi: 10.53854/liim-3002-5. eCollection 2022.
Hepatitis Delta virus (HDV) is responsible for the most aggressive form of chronic hepatitis, which may evolve towards cirrhosis, hepatocellular carcinoma and death within few years. During the last 30 years the only available therapy was interferon or peg-IFN, which was characterized by poor tolerability and modest results. The detailed knowledge of the HDV replication cycle and its interaction with HBV allowed the introduction of new drugs which are currently in phase II or III of experimentation. Basically, bulevirtide, to date the only one approved by EMA, inhibits the entry of the virus into the hepatocytes and hence its intrahepatic spread; lonafarnib inhibits the pharnesylation process of the L-HDAg, which is critical for the assembly of the HDV virion; the nucleic acid polymers (NAPs) mainly block the production/release of HBsAg. The available clinical trials with these compounds showed an excellent anti-viral activity against HDV.
丁型肝炎病毒（HDV）是导致最严重形式慢性肝炎的病原体，这种慢性肝炎可能在数年内发展为肝硬化、肝细胞癌并导致死亡。在过去30年里，唯一可用的治疗方法是干扰素或聚乙二醇干扰素，其特点是耐受性差且效果一般。对HDV复制周期及其与HBV相互作用的详细了解促使了目前正处于实验二期或三期的新药问世。基本上，布列韦肽是迄今为止唯一获得欧洲药品管理局批准的药物，它可抑制病毒进入肝细胞，从而抑制其在肝内传播；洛那法尼可抑制L-HDAg的法尼基化过程，这对HDV病毒体的组装至关重要；核酸聚合物（NAPs）主要阻断HBsAg的产生/释放。对这些化合物进行的现有临床试验显示出对HDV具有出色的抗病毒活性。
